Answer:
Deoxygenated blood enters the right atrium from the superior and inferior vena cava > The blood flows through the tricuspid valve into the right ventricle >From the right ventricle, the blood flows through the pulmonary valve into the pulmonary artery > The right and left pulmonary arteries carry deoxygenated blood to the right and left lungs for gas exchange > The blood releases carbon dioxide as waste and picks up a fresh supply of oxygen > The oxygenated blood flows through the pulmonary veins from the lungs into the left atrium > From the left atrium, the blood flows through the bicuspid, or mitral valve into the left ventricle > Left ventricular contraction forces blood through the aortic valve into the aorta for distribution to the systemic circulation
Explanation:
Find where the bleeding is
Apply pressure
Answer:
Having knowledge of the law, both federal and state laws, will hopefully prevent you from making a mistake that could cause any form of liability for your employer!
Explanation:
the last thing you would want is for your boss to fire you or charge a patients hospital bill to you because you didn't know that whatever you were doing or prescribing was against the law.
Answer:
b) blastic red blood cell (RBC).
Explanation:
In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell <u>(RBC) alloantigens</u> in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology.
